Evaluation of the clinical efficacy of Pediococcus acidilactici CCFM6432 in alleviating depression

Abstract

Aim: Accumulating evidence highlights the crucial role of the “gut-brain axis” and emphasizes the potential of dietary interventions to improve brain health through this pathway. This study assesses the effects of the probiotic Pediococcus acidilactici CCFM6432 on mood, sleep, and gastrointestinal function in patients with depressive disorder.

Methods: This clinical trial is a randomized, placebo-controlled study (Registration: ChiCTR2300071025). It enrolled 39 adult patients diagnosed with depressive disorder, who were randomly assigned to either the placebo control group (n = 19) or the CCFM6432 intervention group (n = 20). The intervention period spanned four weeks. Assessments were conducted at both the beginning and end of the trial, including comprehensive questionnaire evaluations and the collection of serum and fecal samples.

Results: In comparison to the placebo, treatment with CCFM6432 significantly decreased depression and anxiety scores, as well as ameliorated gastrointestinal dysfunction and poor sleep quality commonly associated with mood disorders. Microbiota analysis revealed an increase in species richness without notable changes in overall diversity, yet Pediococcus species was found to be more abundant post-treatment. Functional analysis indicated reduced activity in the NOD-like receptor signaling pathway, suggesting anti-inflammatory effects induced by the probiotic. Metabolomic profiling identified elevated levels of fecal lactic acid, which correlated with lower Hospital Anxiety and Depression Scale (HADS) scores, thereby linking probiotic metabolism to mood enhancement.

Conclusion: These findings imply that CCFM6432 may improve brain function by modulating gut microbiota and their mediated immune homeostasis, underscoring its potential as an adjunctive treatment for mental disorders.

Keywords

Pediococcus acidilactici / depression / gut microbiota / lactic acid / immune

References

[1] Freeman M.The World Mental Health Report: transforming mental health for all.World Psychiatry2022;21:391-2 PMCID:PMC9453907

[2] Mazza MG,Poletti S.Post-COVID-19 depressive symptoms: epidemiology, pathophysiology, and pharmacological treatment.CNS Drugs2022;36:681-702 PMCID:PMC9210800

[3] Penninx BW,Lamers F.Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile.BMC Med2013;11:129 PMCID:PMC3661358

[4] Spellman T.Toward circuit mechanisms of pathophysiology in depression.Am J Psychiatry2020;177:381-90 PMCID:PMC7643194

[5] Cipriani A,Salanti G.Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.Focus2018;16:420-9 PMCID:PMC6996085

[6] Raes J.Nifty new tools for microbiome treatment design.Nat Rev Gastroenterol Hepatol2023;20:77-8

[7] Strandwitz P.Neurotransmitter modulation by the gut microbiota.Brain Res2018;1693:128-33 PMCID:PMC6005194

[8] Barandouzi ZA,Henderson WA,Cong XS.Altered composition of gut microbiota in depression: a systematic review.Front Psychiatry2020;11:541 PMCID:PMC7299157

[9] Simpson CA,Eliby D,Simmons JG.The gut microbiota in anxiety and depression - a systematic review.Clin Psychol Rev2021;83:101943

[10] Tian P,Zhu H.Bifidobacterium breve CCFM1025 attenuates major depression disorder via regulating gut microbiome and tryptophan metabolism: a randomized clinical trial.Brain Behav Immun2022;100:233-41

[11] Zhu F,Wang W.Transplantation of microbiota from drug-free patients with schizophrenia causes schizophrenia-like abnormal behaviors and dysregulated kynurenine metabolism in mice.Mol Psychiatry2020;25:2905-18

[12] Baske MM,Garmo LG,McCollum KA.Fecal microbiota transplant on Escherichia-Shigella gut composition and its potential role in the treatment of generalized anxiety disorder: a systematic review.J Affect Disord2024;354:309-17

[13] Doll JPK,Schaub AC.Fecal microbiota transplantation (FMT) as an adjunctive therapy for depression - case report.Front Psychiatry2022;13:815422 PMCID:PMC8891755

[14] Carlson PE Jr.Regulatory considerations for fecal microbiota transplantation products.Cell Host Microbe2020;27:173-5

[15] Kazem YI,Essa HA.Role of Bifidobacterium spp. intake in improving depressive mood and well-being and its link to kynurenine blood level: an interventional study.J Complement Integr Med2023;20:223-32

[16] Qian X,Guo M.Determining the emotional regulation function of Bifidobacterium breve: the role of gut metabolite regulation over colonization capability.Food Funct2024;15:1598-611

[17] Dinan TG,Cryan JF.Psychobiotics: a novel class of psychotropic.Biol Psychiatry2013;74:720-6

[18] Knuesel T.The role of the gut microbiota in the development and progression of major depressive and bipolar disorder.Nutrients2021;14:37 PMCID:PMC8746924

[19] Tian P,Wang L.Multi-probiotics ameliorate major depressive disorder and accompanying gastrointestinal syndromes via serotonergic system regulation.J Adv Res2023;45:117-25 PMCID:PMC10006521

[20] Majeed M,Arumugam S,Ali F.Bacillus coagulans MTCC 5856 for the management of major depression with irritable bowel syndrome: a randomised, double-blind, placebo controlled, multi-centre, pilot clinical study.Food Nutr Res2018;62: PMCID:PMC6034030

[21] Zung WW.A rating instrument for anxiety disorders.Psychosomatics1971;12:371-9

[22] Beekman E.Clinimetrics: hospital anxiety and depression scale.J Physiother2018;64:198

[23] Buysse DJ,Strollo PJ.Relationships between the Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), and clinical/polysomnographic measures in a community sample.J Clin Sleep Med2008;4:563-71 PMCID:PMC2603534

[24] Svedlund J,Dotevall G.GSRS - a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease.Dig Dis Sci1988;33:129-34

[25] Riemann D.Primary insomnia: a risk factor to develop depression?.J Affect Disord2003;76:255-9

[26] Zhang AZ,Huang KM.Prevalence of depression and anxiety in patients with chronic digestive system diseases: a multicenter epidemiological study.World J Gastroenterol2016;22:9437-44 PMCID:PMC5107708

[27] Díaz-Perdigones CM,Álvarez-Bermúdez MD,Tinahones FJ.Gut microbiota of patients with type 2 diabetes and gastrointestinal intolerance to metformin differs in composition and functionality from tolerant patients.Biomed Pharmacother2022;145:112448

[28] Zhou J,Zhao Y.The relationship of Megamonas species with nonalcoholic fatty liver disease in children and adolescents revealed by metagenomics of gut microbiota.Sci Rep2022;12:22001 PMCID:PMC9767906

[29] Zhao RH,Liu SM.[Correlation between gut microbiota and behavior symptoms in children with autism spectrum disorder].Zhongguo Dang Dai Er Ke Za Zhi2019;21:663-9 PMCID:PMC7389106

[30] Zheng P,Zhou C.Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host’s metabolism.Mol Psychiatry2016;21:786-96

[31] Cheung SG,Uhlemann AC,Miller JM.Systematic review of gut microbiota and major depression.Front Psychiatry2019;10:34 PMCID:PMC6378305

[32] Mcguinness B.Rodent models of stress-induced depression: the link between stress and immune system related changes. In: Müller N, Myint A, Schwarz MJ, editors. Immunology and psychiatry. Cham: Springer International Publishing; 2015. pp. 33-62.

[33] Miller AH,Raison CL.Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression.Biol Psychiatry2009;65:732-41 PMCID:PMC2680424

[34] Nettis MA.Is there neuroinflammation in depression? Understanding the link between the brain and the peripheral immune system in depression.Int Rev Neurobiol2020;152:23-40

[35] Capuron L,Miller AH.Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy.Brain Behav Immun2004;18:205-13

[36] Spencer SP,Sonnenburg JL.Pursuing human-relevant gut microbiota-immune interactions.Immunity2019;51:225-39 PMCID:PMC7205593

[37] Gorjifard S.Microbiota - myeloid cell crosstalk beyond the gut.J Leukoc Biol2016;100:865-79 PMCID:PMC6608064

[38] Peterson LW.Intestinal epithelial cells: regulators of barrier function and immune homeostasis.Nat Rev Immunol2014;14:141-53

[39] Liu P,Wang J.Immunoregulatory role of the gut microbiota in inflammatory depression.Nat Commun2024;15:3003 PMCID:PMC11001948

[40] Tian P,Qian X.Pediococcus acidilactici CCFM6432 mitigates chronic stress-induced anxiety and gut microbial abnormalities.Food Funct2021;12:11241-9

[41] Yang H,Pei Y. Pediococcus acidilactici CCFM6432 improves depressive behavior in mice by alleviating brain inflammation. Food Ferment Ind 2023:1-10. (in Chinese). Available from: https://link.cnki.net/doi/10.13995/j.cnki.11-1802/ts.037523. [Last accessed on 18 Sep 2024]

[42] McGuinness AJ,Dawson SL.A systematic review of gut microbiota composition in observational studies of major depressive disorder, bipolar disorder and schizophrenia.Mol Psychiatry2022;27:1920-35 PMCID:PMC9126816

[43] Dao VH,Trinh TO,Dao VL.Psychobiotics for patients with chronic gastrointestinal disorders having anxiety or depression symptoms.J Multidiscip Healthc2021;14:1395-402 PMCID:PMC8203266

[44] Lee HJ,Kim JK.Effects of probiotic NVP-1704 on mental health and sleep in healthy adults: an 8-week randomized, double-blind, placebo-controlled trial.Nutrients2021;13:2660 PMCID:PMC8398773